Patents by Inventor Kristiaan Thielemans

Kristiaan Thielemans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNA TRANSCRIPTION VECTOR AND USES THEREOF
    Publication number: 20210060182
    Abstract: The present invention in general relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector in particular reside in the presence of a transcription enhancer and a nuclear retention element.
    Type: Application
    Filed: November 13, 2020
    Publication date: March 4, 2021
    Applicant: Vrije Universiteit Brussel
    Inventors: Carlo Heirman, Kristiaan Thielemans
  • RNA transcription vector and uses thereof
    Patent number: 10864284
    Abstract: The present invention in general relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector in particular reside in the presence of a transcription enhancer and a nuclear retention element.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: December 15, 2020
    Assignee: Vrije Universiteit Brussel
    Inventors: Carlo Heirman, Kristiaan Thielemans
  • RNA transcription vector and uses thereof
    Patent number: 10159755
    Abstract: The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: December 25, 2018
    Assignee: Vrije Universiteit Brussel
    Inventors: Carlo Heirman, Kristiaan Thielemans
  • RNA TRANSCRIPTION VECTOR AND USES THEREOF
    Publication number: 20180353625
    Abstract: The present invention in general relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector in particular reside in the presence of a transcription enhancer and a nuclear retention element.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Applicant: Vrije Universiteit Brussel
    Inventors: Carlo Heirman, Kristiaan Thielemans
  • RNA TRANSCRIPTION VECTOR AND USES THEREOF
    Publication number: 20160279266
    Abstract: The present invention relates to an improved RNA transcription vector, which is very suitable for the production of mRNA for in vivo therapeutic purposes. The improvements in the vector reside in the presence of a translation enhancer (TE) and a nuclear retention element (NRS), especially when the latter is the “Expression and Nuclear Retention Element” (ENE) of Kaposi's sarcoma associated Herpes virus (KSHV).
    Type: Application
    Filed: November 12, 2014
    Publication date: September 29, 2016
    Applicant: VRIJE UNIVERSITEIT BRUSSEL
    Inventors: Carlo HEIRMAN, Kristiaan THIELEMANS
  • IDIOTYPIC VACCINATION AGAINST B CELL LYMPHOMA
    Publication number: 20030072751
    Abstract: The invention provides a method of inducing an effective immune response to pathogenic lymphocytes by administering dendritic cells previously pulsed with the idiotype protein of interest. In one embodiment, a method for the active immunization of a mammal against lymphoma is provided. This embodiment comprises exposing dendritic cells to idiotype Ig to make idiotype pulsed dendritic cells and injecting the idiotype pulsed dendritic cells back into the mammal, whereby immunity against lymphoma cells is induced. In another embodiment, the invention relates to the administration of both idiotypic cells and pulsed dendritic cells.
    Type: Application
    Filed: March 14, 1990
    Publication date: April 17, 2003
    Inventors: HERIBERT BOHLEN, JACQUES URBAIN, BENJAMIN VAN CAMP, KRISTIAAN THIELEMANS
  • Assay for monoclonal antibody against surface Ig of a human B cell tumor
    Patent number: 4513088
    Abstract: An assay that facilitates screening of hybridoma culture media for monoclonal anti-idiotype antibodies, particularly murine monoclonal antibodies that are useful for treating human B cell tumors is disclosed. The assay is a solid phase type assay and involves: incubating a lysate of the patienREFERENCE TO GOVERNMENT GRANT OR CONTRACTThe invention described herein was made in the course of work under a grant or contract from the National Institutes of Health.
    Type: Grant
    Filed: March 30, 1983
    Date of Patent: April 23, 1985
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Ronald Levy, David G. Maloney, Kristiaan Thielemans